Title | A novel metabolic-immune related signature predicts prognosis and immunotherapy response in lung adenocarcinoma |
Authors | Tang, Xiaolong Qi, Chumei Zhou, Honghong Liu, Yongshuo |
Affiliation | Binzhou Med Univ, Dept Clin Lab Diagnost, Binzhou 256603, Shandong, Peoples R China Dazhou Women & Childrens Hosp, Dept Clin Lab, Dazhou 635000, Sichuan, Peoples R China Chinese Acad Sci, Inst Biophys, Ctr Big Data Res Hlth, Key Lab RNA Biol, Beijing 100101, Peoples R China Binzhou Med Univ Hosp, Dept Clin Lab, Binzhou 256603, Shandong, Peoples R China Peking Univ, Peking Univ Genome Editing Res Ctr,Sch Life Sci, Biomed Pioneering Innovat Ctr BIOP,State Key Lab P, Beijing Adv Innovat Ctr Genom,Peking Tsinghua Ctr, Beijing 100871, Peoples R China |
Keywords | HEPATOCELLULAR-CARCINOMA CCL20 PROGRESSION DICKKOPF-1 EXPRESSION LEVEL |
Issue Date | Aug-2022 |
Publisher | HELIYON |
Abstract | Background: Lung adenocarcinoma (LUAD) is one of the most frequent types of lung cancer, with a high mortality and recurrence rate. This study aimed to design a RiskScore to predict the prognosis and immunotherapy response of LUAD patients due to a lack of metabolic and immune-related prognostic models.Methods: To identify prognostic genes and generate a RiskScore, we conducted differential gene expression analysis, bulk survival analysis, Lasso regression analysis, and univariate and multivariate Cox regression analysis using TCGA-LUAD as a training subset. GSE31210 and GSE50081 were used as validation subsets to validate the constructed RiskScore. Following that, we explored the connection between RiskScore and clinicopathological characteristics, immune cells infiltration, and immunotherapy. In addition, we investigated into RiskScore's biological roles and constructed a Nomogram model.Results: A RiskScore was identified consisting of five genes (DKK1, CCL20, NPAS2, GNPNAT1 and MELTF). In the RiskScore-high group, LUAD patients showed decreased overall survival rates and shorter progression-free sur-vival. Multiple clinicopathological characteristics and immune cells infiltration in TME, in particular, have been linked to RiskScore. Of note, RiskScore-related genes have been implicated to substance metabolism, carcino-genesis, and immunological pathways, among other things. Finally, the C-index of the RiskScore-based Nomo-gram model was 0.804 (95% CI: 0.783-0.825), and time-dependent ROC predicted probabilities of 1-, 3-and 5 -year survival for LUAD patients were 0.850, 0.848 and 0.825, respectively.Conclusion: The RiskScore, which integrated metabolic and immunological features with DKK1, CCL20, NPAS2, GNPNAT1, and MELTF, could reliably predict prognosis and immunotherapy response in LUAD patients. More-over, the RiskScore-based Nomogram model had a promising clinical application. |
URI | http://hdl.handle.net/20.500.11897/655782 |
DOI | 10.1016/j.heliyon.2022.e10164 |
Indexed | SCI(E) |
Appears in Collections: | 生命科学学院 |